Innate Pharma S.A. (IPHA) This autumn 2025 Earnings Name March 26, 2026 9:00 AM EDT
Firm Contributors
Stephanie Cornen – Vice President of Investor Relations, Communication & Industrial Technique
Jonathan Dickinson – CEO & Director
Sonia Quaratino – Govt VP & Chief Medical Officer
Yannis Morel – Govt VP & COO
Frederic Lombard – Senior VP & CFO
Convention Name Contributors
Swayampakula Ramakanth – H.C. Wainwright & Co, LLC, Analysis Division
Daina Graybosch – Leerink Companions LLC, Analysis Division
Jeet Mukherjee – BTIG, LLC, Analysis Division
Christopher Liu – Lucid Capital Markets, LLC, Analysis Division
Presentation
Operator
Girls and gents, thanks for becoming a member of us, and welcome to the Innate Pharma Full Yr 2025 Earnings Name. [Operator Instructions]
I’ll now hand the convention over to Stephanie Cornen, Vice President of Investor Relations, Communications and Industrial Technique at Innate Pharma. Please, Stephanie, go forward.
Stephanie Cornen
Vice President of Investor Relations, Communication & Industrial Technique
Thanks. Good morning and good afternoon, everybody, and thanks for becoming a member of us for Innate Pharma’s Full Yr 2025 Enterprise Replace and Monetary Outcomes Convention Name. The press launch and immediately’s presentation can be found on the Investor Relations part of our web site.
Earlier than we start, I wish to remind everybody that immediately’s presentation contains forward-looking statements based mostly on present expectations. These statements contain dangers and uncertainties that would trigger precise outcomes to vary materially. I’ll briefly cowl immediately’s agenda. Our CEO, Jonathan Dickinson, will start with a strategic overview and outlook. We’ll then share updates on our 3 precedence program, lacutamab, IPH4502 and monalizumab in addition to IPH5201 in partnership with AstraZeneca. Audio system will probably be our CMO, Sonia Quaratino; our COO, Yannis Morel; and I. Frederic Lombard, CFO, will remark our monetary outcomes. Jonathan will return with upcoming catalysts and shutting remarks earlier than we open the decision for Q&A.
